<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072345</url>
  </required_header>
  <id_info>
    <org_study_id>03-084</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-03084</secondary_id>
    <nct_id>NCT00072345</nct_id>
  </id_info>
  <brief_title>Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma</brief_title>
  <official_title>A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide and lomustine, use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the&#xD;
      growth of cancer by stopping blood flow to the tumor. Combining temozolomide and thalidomide&#xD;
      with lomustine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining temozolomide and thalidomide&#xD;
      with lomustine in treating patients who have unresectable stage III or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the antitumor activity of temozolomide, thalidomide, and lomustine, in terms&#xD;
           of objective response rate, in patients with unresectable stage III or stage IV&#xD;
           melanoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the duration of response and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: Patients receive oral temozolomide on days 1-42, oral thalidomide on days 1-56, and&#xD;
      oral lomustine on days 1 and 29. Courses repeat every 8 weeks in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic malignant melanoma&#xD;
&#xD;
               -  Unresectable stage III OR stage IV disease&#xD;
&#xD;
               -  Ocular, mucosal, and cutaneous melanoma allowed&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Indicator lesions within a prior radiotherapy field must have recent evidence of&#xD;
                  disease progression&#xD;
&#xD;
               -  Indicator lesions must be distinct from the surgical and/or radiation changes&#xD;
                  induced by prior local therapies&#xD;
&#xD;
          -  No more than 2 symptomatic hemorrhagic lesions in the brain&#xD;
&#xD;
               -  No hemorrhagic lesion(s) greater than 1 cm in diameter&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN&#xD;
&#xD;
          -  Lactic dehydrogenase no greater than 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No history of severe cardiovascular disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No ventricular arrhythmia&#xD;
&#xD;
          -  No uncontrolled arrhythmia&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No frequent vomiting&#xD;
&#xD;
          -  No other medical condition that would preclude oral medication intake (e.g., partial&#xD;
             bowel obstruction)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 4 weeks after&#xD;
             study participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  No serious infection requiring IV antibiotics&#xD;
&#xD;
          -  No other uncontrolled medical illness that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 2 years except nonmelanoma skin cancer, carcinoma&#xD;
             in situ of the cervix, or T1a or b prostate cancer meeting all of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Detected incidentally at transurethral resection of the prostate (TURP)&#xD;
&#xD;
               -  Comprises less than 5% of resected tissue&#xD;
&#xD;
               -  Prostate-specific antigen normal since TURP&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy or biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy for melanoma&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior focused radiotherapy for brain metastases&#xD;
&#xD;
          -  At least 3 weeks since prior radiosurgery&#xD;
&#xD;
          -  At least 4 weeks since prior whole brain radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior interstitial brachytherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior surgery for brain metastases&#xD;
&#xD;
          -  At least 3 weeks since prior surgery requiring general anesthesia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Jen Hwu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>ciliary body and choroid melanoma, small size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

